Article
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
2022-08-08
Abstract excerpt
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful in reducing hospitalization or death due to COVID-19 1,2 . However, as SARS-CoV-2 has evolved to become resistant to other therapeutic modalities 3–9 , there is a concern that the same could occur for nirmatrelvir. Here, we have examined this possibility by in vitro passaging of SARS-CoV-2 in...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 61c4d618-74be-5fea-85c8-0ca5496616ef
- DOI
- 10.1101/2022.08.07.499047
